AMN107, novel aminopyrimidine inhibitor of Bcr-Abl, is significantly more potent than imatinib mesylate against Philadelphia chromosome positive acute lymphoblastic leukemia cells.

被引：0

作者：

Golemovic, M

Beran, M

Giles, F

Manshouri, T

Thomas, D

Cortes, J

Manley, P

Alland, L

Rae, P

Dugan, M

Estrov, Z

Arlinghaus, RB

Kantarjian, H

Verstovsek, S

机构：

[1] Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

[2] Novartis Pharmaceut, Basel, Switzerland

来源：

BLOOD | 2004年 / 104卷 / 11期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2737

引用

页码：748A / 748A

页数：1

共 50 条

[1] AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells
Verstovsek, S
Golemovic, M
Kantarjian, H
Manshouri, T
Estrov, Z
Manley, P
Sun, T
Arlinghaus, RB
Alland, L
Dugan, M
Cortes, J
Giles, F
Beran, M
CANCER, 2005, 104 (06) : 1230 - 1236
[2] Activity of AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, in imatinib-resistant Bcr-Abl positive lymphoid malignancies
Ottmann, OG
Giles, FJ
Wassmann, B
Wunderle, L
Bhalla, K
Jones, D
Hochhaus, A
Rae, PE
Mietlowski, W
Beran, M
Albitar, M
Alland, L
Dugan, M
Kantarjian, H
BRITISH JOURNAL OF HAEMATOLOGY, 2005, 129 : 22 - 22
[3] Activity of AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, in imatinib-resistant Bcr-Abl positive lymphoid malignancies.
Ottmann, O
Giles, F
Wassmann, B
Hochhaus, A
Rae, P
Beran, M
Albitar, M
Alland, L
Dugan, M
Kantarjian, H
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 195S - 195S
[4] AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has significant activity in imatinib-resistant Bcr-Abl positive chronic myeloid leukemia (CML)
Giles, FG
Ottmann, OT
Cortes, J
Wassmann, B
Bhalla, K
Jones, D
Hochhaus, A
Rae, PE
Tanaka, C
Alland, L
Dugan, M
Albitar, M
Kantarjian, H
BRITISH JOURNAL OF HAEMATOLOGY, 2005, 129 : 3 - 3
[5] AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has significant activity in imatinib-resistant Bcr-Abl positive chronic myeloid leukemia (CML).
Kantarjian, H
Ottmann, O
Cortes, J
Wassmann, B
Jones, D
Hochhaus, A
Alland, L
Dugan, M
Albitar, M
Giles, F
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 195S - 195S
[6] AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia
Golemovic, M
Verstovsek, S
Giles, F
Cortes, J
Manshouri, T
Manley, PW
Mestan, J
Dugan, M
Alland, L
Griffin, JD
Arlinghaus, RB
Sun, T
Kantarjian, H
Beran, M
CLINICAL CANCER RESEARCH, 2005, 11 (13) : 4941 - 4947
[7] AMN107, a novel aminopyrimidine inhibitor of BCR-ABL, has pre-clinical activity against imatinib mesylate-resistant chronic myeloid leukemia (CML).
Golemovic, M
Giles, FJ
Beran, M
Cortes, J
Manshouri, T
Kantarjian, H
Verstovsek, S
BLOOD, 2004, 104 (11) : 547A - 547A
[8] AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has significant activity in imatinib-resistant chronic myeloid leukemia (CML) or Philadelphia-chromosome positive acute lymphoid leukemia (Ph plus ALL)
Kantarjian, HM
Ottmann, O
Hochhaus, A
Mueller, M
Cortes, J
Wassmann, B
Wunderle, L
Bhalla, K
Jones, D
Rafferty, T
Albitar, M
Rae, L
Dugan, M
Alland, L
Giles, F
ANNALS OF ONCOLOGY, 2006, 17 : 32 - 32
[9] AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has significant activity in Imatinib-resistant chronic myeloid leukemia (CML) or Philadelphia-chromosome positive acute lymphoid leukemia (Ph plus ALL).
Kantarjian, HM
Ottman, O
Cortes, J
Wassman, M
Wunderle, L
Bhalla, K
Jones, D
Hochhaus, A
Rae, P
Alland, L
Dugan, M
Albitar, M
Giles, F
BLOOD, 2005, 106 (11) : 15A - 16A
[10] Leptomycin B overcomes imatinib resistance mediated by stromal cells and mutant BCR-ABL in Philadelphia chromosome-positive acute lymphoblastic leukemia cells.
Tojo, A
Izawa, K
Sekine, R
Nagamura, T
Yoshida, M
Tsuji, T
BLOOD, 2004, 104 (11) : 575A - 575A

← 1 2 3 4 5 →